delpazolid: Clinical Trials

13 trials of delpazolid, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 2 recruiting, 1 not yet recruiting, 1 terminated. 6 Phase 1, 6 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 16Completed 6
Phase 26Completed 3, Recruiting 2, Terminated 1
Phase 31Not yet recruiting 1

Follow delpazolid: new trials by email Literature Review of delpazolid trials Research Report on delpazolid

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A 6-Month MDR-END Plus Regimen for Rifampicin-Resistant Tuberculosis
MDR-END Plus regimen, Standard-of-care (SoC) treatment - Rifampicin-Resistant Tuberculosis
Phase 3Not yet recruitingSeoul National University Hospital2942026-10-012026-06-30
Study to Evaluate the Efficacy of Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus Complex
Delpazolid - Nontuberculous Mycobacterium Infection, Mycobacterium Abscessus Infection
Phase 2CompletedLigaChem Biosciences, Inc.242024-01-162026-07-10
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
Ganfeborole, BTZ-043, Bedaquiline (B) - Pulmonary Tuberculosis
Phase 2RecruitingUniversity College, London25002024-01-092026-10-15
PanACEA - STEP2C -01
BTZ-043, Rifampicin, Isoniazid - Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis
Phase 2RecruitingMichael Hoelscher3902023-04-142025-10-07
A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia
Delpazolid, Vancomycin, Placebo of Delpazolid - MRSA Bacteremia
Phase 2TerminatedLigaChem Biosciences, Inc.402022-04-262025-05-06
PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
Delpazolid, Bedaquiline, Delamanid, Moxifloxacin - Infections and Infestations, Pulmonary Tuberculosis
Phase 2CompletedLigaChem Biosciences, Inc.762021-10-282025-09-16
Trial to Evaluate Bioequivalence of LCB01-0371 in Different Batches
LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R), LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006) - Healthy
Phase 1CompletedLigaChem Biosciences, Inc.252021-01-142021-06-25
A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK
LCB01-0371 800mg, QD, LCB01-0371 400mg, BID, LCB01-0371 800mg, BID - Pulmonary Tuberculosis
Phase 2CompletedLigaChem Biosciences, Inc.792016-12-102020-02-06
IV Dosage Form of LCB01-0371 Phase I Study in Healthy Male Volunteers
LCB01-0371, LCB01-0371 400mg - Healthy
Phase 1CompletedLigaChem Biosciences, Inc.242016-09-012018-04-10
To Evaluate the Effect of Food on Pharmacokinetics(PK), Phase I Clinical Study of LCB01-0371
LCB01-0371 Tablet 800 mg(R), LCB01-0371 Tablet 800 mg(T) - Healthy
Phase 1CompletedLigaChem Biosciences, Inc.302015-09-012016-03-23
Multiple Ascending Dose, Phase 1 Clinical Study of LCB01-0371
LCB01-0371 800mg, LCB01-0371 800mg BID, LCB01-0371 1200mg BID - Healthy
Phase 1CompletedLigaChem Biosciences, Inc.302014-06-012015-09-04
Multiple Ascending Dose Study for LCB01-0371
LCB01-0371 800mg, LCB01-0371 1200mg, Placebo - Healthy
Phase 1CompletedLigaChem Biosciences, Inc.302013-03-012014-11-17
A Clinical Study, Randomized, Double-blind, Placebo-controlled, Single Dose Study
LCB01-0371, Linezolid - Healthy
Phase 1CompletedLigaChem Biosciences, Inc.702012-03-012014-11-17

Conditions studied

Tuberculosis, Pulmonary (4)  ·  Bacteremia (1)  ·  Infections (1)  ·  Mycobacterium Infections, Nontuberculous (1)  ·  Sepsis (1)  ·  Tuberculosis (1)  ·  Tuberculosis, Multidrug-Resistant (1)

Sponsors

LigaChem Biosciences, Inc. (10)  ·  Michael Hoelscher (1)  ·  Seoul National University Hospital (1)  ·  University College, London (1)

Countries

South Korea (9)  ·  South Africa (4)  ·  Tanzania (3)  ·  Uganda (2)  ·  Gabon (1)  ·  Malawi (1)  ·  Moldova (1)  ·  Mozambique (1)  ·  Vietnam (1)

Top investigators

Hongbin Kim (1)  ·  Jae-Joon Yim, MD, PhD (1)  ·  Jae-Yong Chung (1)  ·  Jaeyong Chung, M.D., Ph.D (1)  ·  Jennifer Hughes, MBBCh (1)  ·  Jeongha Mok, MD, PhD (1)  ·  Kyun-Seop Bae, M.D., Ph. D. (1)  ·  Kyun-Seop Bae, MD, PhD. (1)  ·  Michael Hoelscher, Prof Dr. (1)  ·  T.S Sim, M.D., Ph.D (1)  ·  Young Lag Cho, Ph.D. (1)

Results publications

PMID 29069400, PMID 29712654, PMID 30420289, PMID 30559004, PMID 34871098, PMID 37280643, PMID 38436463, PMID 39801777, PMID 40645198, PMID 41705840